Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current developments in cancer vaccines and cellular immunotherapy.

Antoni Ribas1, Lisa H Butterfield, John A Glaspy

  • 1Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, 90095-1782, USA. aribas@mednet.ucla.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|June 14, 2003
PubMed
Summary

This review explores the immunology behind cancer vaccine and cellular immunotherapy clinical trials. Understanding tumor antigen recognition and immune activation is key to developing effective cancer treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.

Nature communications·2026
Same author

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

Cancer discovery·2026
Same author

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.

Nature communications·2026
Same author

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.

Targeted oncology·2026

Area of Science:

  • Immunology
  • Oncology
  • Clinical Trials

Background:

  • Recent advances in tumor antigen characterization and immune response regulation have accelerated novel immunotherapy strategies.
  • Understanding the immunologic basis of cancer is crucial for developing effective treatments.

Purpose of the Study:

  • To provide clinicians with a mechanistic understanding of ongoing cancer vaccine and cellular immunotherapy clinical trials.
  • To review the immunologic basis of tumor antigen recognition and immune activation in cancer therapy.

Main Methods:

  • Review of current literature on cancer immunotherapy and clinical trials.
  • Analysis of the key steps in generating an immune response to cancer cells.
  • Discussion of novel immunotherapy strategies and their clinical applications.

Related Experiment Videos

Main Results:

  • Key steps in anti-cancer immune response include antigen loading, presentation, cytotoxic lymphocyte activation, and overcoming regulatory controls.
  • Antigen-specific immunization strategies utilize tumor-derived or synthetic antigens (proteins, RNA, DNA).
  • Enhanced antigen presentation is achieved through adjuvants, costimulatory molecules, cytokines, and dendritic cell culturing.

Conclusions:

  • Advances in understanding tumor antigens and immune regulation have led to multiple novel immunotherapy strategies in clinical trials.
  • Targeting tumor antigen recognition and immune activation forms the basis of modern cancer immunotherapy.
  • Mechanistic insights are vital for the successful clinical translation of cancer vaccines and cellular immunotherapies.